BLUEVAC is an essential tool in the control of Bluetongue virus (serotype 1, 4 and 8) in sheep and cattle, producing an active immunisation and decreasing the spread of the disease.
BLUEVAC is based on the use of Aluminum hydroxide and Quil A as adjuvants. Quil A is a derivative of a puriﬁed saponin that repositions viral antigens and retards them to be captured by immunity cells from vaccinated animals.
Testing and validated by RT-PCR method, BLUEVAC prevents the viraemia, indicating no presence of viral genome after vaccination and making safe.
The use of the puriﬁed Saponin Quil A as an adjuvant, produces no serious local reactions.
Control of the appearance of clinical cases of Bluetongue disease
Cost-beneﬁt of one dose vs losses associated with clinical signs and decreased production
Control of dissemination of disease and declining trade restrictions
More than 230 million doses of BLUEVAC administered in Europe, have shown to be a valuable method and the best choice to reduce clinical signs and viraemia in sheep and cattle herds.
Vaccination with BLUEVAC prevents viraemia and transmission to healthy animals, decreasing the prevalence of the disease in endemic areas.
With a collapsible plastic bottle, BLUEVAC has a stronger and lighter packaging, and does not require vented draw-of equipment.